LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Articles
Mirna Therapeutics Inc.
Headquarters:
Austin, TX, United States of America
Website:
N/A
Year Founded:
2007
Status:
Reverse-merged
BioCentury
|
Aug 28, 2020
Finance
Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence
A decision to stall a blood cancer program in favor of solid tumors helped drive investor interest
Read More
BioCentury
|
Feb 13, 2018
Company News
Management tracks: Cytokinetics, Surface Oncology
Read More
BioCentury
|
Jan 9, 2018
Company News
Management tracks: OncoMed, Neurocrine
Read More
BioCentury
|
Jul 17, 2017
Company News
Management tracks
Read More
BioCentury
|
May 19, 2017
Finance
Back door listing
Why Synlogic’s investors took the company public through the back door
Read More
BioCentury
|
May 19, 2017
Company News
Synlogic finds public route via Mirna, raises $42M
Read More
BioCentury
|
May 18, 2017
Product R&D
Making cells compute
The momentum is building in synthetic biology; CAR Ts stand to benefit
Read More
BioCentury
|
May 16, 2017
Financial News
Synlogic finds public route, raises $42M
Read More
BioCentury
|
Sep 26, 2016
Clinical News
MRX34: Phase I discontinued
Read More
BioCentury
|
Apr 28, 2016
Company News
Management tracks
Read More
Items per page:
10
1 - 10 of 62
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa
Help